It takes longer to say yet reflects the condition more precisely. I like it.
The condition has been renamed from PCOS to PMOS. I think the update is good and that it was needed.
PCOS just got a new name today, how do you feel about it?
Summary
What are people's reactions to renaming PCOS to PMOS and does the change address treatment gaps?
Most participants welcome the shift to PMOS for its accuracy in reflecting a broader metabolic disorder, though one finds it unappealing. Discussion quickly moves to ongoing lack of treatment progress, with some describing personal success using GLP-1 medications and inositol while noting barriers like insurance and specialist access. Commercial incentives for expanding GLP-1 approvals are mentioned as a factor that could indirectly improve access.
What this discussion establishes- New name seen as more precise by several users
- No major treatment advances reported in the past decade
- GLP-1s described as helpful for metabolic control in some cases
- Inositol noted as an accessible option especially for normal-weight patients
- Insurance coverage and specialist referrals remain hurdles
One participant leans against the name change while others support it for accuracy.
Still openWhether expanded GLP-1 trials will translate into better real-world access or new standard treatments for PMOS.
Nothing here is advice.
5 replies · 6 people
I started writing a longer reply but decided most people probably would not care. If the new name helps patients see this as a widespread metabolic issue rather than only an ovary problem then the change is worthwhile. Still, practical support is missing. My endocrinologist acknowledged there have been no treatment advances in ten years. Getting referred was a struggle and mainstream options ran out, which is how I ended up trying other approaches. GLP1s have helped me manage the metabolic disruption. Inositol is another option I suggest because it is low risk and available as a supplement. It may suit people of normal weight who would not qualify for or prefer not to use GLP1s. For me it made a noticeable difference and was the only thing that helped.
↳ replying to @GreyWillow80
The manufacturers of the main GLP1s will probably start testing them for PMOS along with other conditions they are already studying such as fatty liver and addiction. Each new approval expands the market and creates more billing opportunities plus implications for patents.
↳ replying to @CopperHarbour29
It also gives doctors more justification to prescribe these medications, especially since many related conditions worsen with excess weight, so the development is not entirely negative for people who have good insurance coverage.
Add your experience
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.